Novo Nordisk CFO Highlights Factors Influencing U.S. Drug Price Reductions

Novo Nordisk's Chief Financial Officer has indicated that the 'most favored nation' status has played a role in reducing drug prices in the United States. According to Jin10, the CFO emphasized that a more significant factor contributing to this trend is the larger scale of cash operations. The remarks shed light on the dynamics affecting pharmaceutical pricing in the U.S. market.